| Biography | |
|---|---|
 Prof. Lijun Zhang Shanghai Public Health Clinical Center, Fudan University, China |
|
| Title: A Quantitative Proteomic Study Revealed PXXX2 to be a Colon Cancer Early Biomarker | |
| Abstract: Colorectal carcinoma (CRC) is one of the most common cancers in the world, but its early diagnosis and treatment is still challenge. In this work, we built a colon cancer mouse model through Azoxymethane (AOM) / Dextran sodium sulfate (DSS) administration. Using two dimensional gel electrophoresis (2DE) based proteomic technology, we exhaustively investigated the proteome of colon mucosa from mouse model of colon cancer. Total proteins of mucosa were separated by two dimensional gel electrophoresis (2DE) and found that 7 proteins were differently expressed in colon cancer compared to the control (Pvalue < 0.05, mean fold change versus normal mucosa ±2). Through Gene Ontology (GO) database search, 6 of them have binding function. Since PXXX2 is an only related protein that is in cell redox homeostasis and apoptotic signaling pathway, we further verified the expression of PDIA2 in colon cancer of rat model and clinical samples and found that the protein level of PXXX2 was elevated for 1.6 and 1.6 -fold in colon cancer of rat model treated for 7 and 12 weeks compared to their controls. Furthermore, the expression level of PXXX2 was substantially higher for 1.7 and 2.8 fold in human colorectal tissues than paired adjacent colon tissues detected by western blot and tissue microarray. Further grouping analysis to tissue microarray showed that the up-regulation of PXXX2 has correlation with higher metastasis of lymphatic node, especially in female patients, PXXX2 has higher expression in all patients with metastasis of lymphatic node. Knockdown of PXXX2 decreased cell viability in cell line, and tumor growth in nude mice. Furthermore, knockdown of PXXX2 increased mitochondrial proton leak, maximal respiration and ATP production analyzed by XF24 Extracellular Flux Analyzer. Thus, this study demonstrates that the over-expression of PXXX2 may serve as an early carcinoma biomarker for CRC. PXXX2 might be a potential drug target for colon cancer treatment. | |
| Biography: Professor Lijun Zhang is the Director of Clinical Phase I in the Shanghai Public Health Clinical Center affiliated to Fudan University, and Asymchem Laboratories. Professor Zhang has published over 20 papers on the subject of HPLC/MS for pharmacokinetics, and proteomics study. She is a recognized expert in the use of liquid chromatography with mass spectrometry, giving many invited papers at international meetings around the world. After obtaining a Bachelor Degree in Chemistry from Central South University, Hunan, China in 1995, she started work as a chemical analysis worker in Lian Yuan Iron and Steel Group. From 2001 to 2006, she went to Hunan Normal University to perform her research in proteomics and obtained her Ph.D. in 2006. After graduated, she moved to Shanghai Public Health Clinical Center, Shanghai, China where she focuses on proteomics and pharmacokinetics research. During these days working in Shanghai Public Health Clinical Center, she had also performed short time research in University at Buffalo as a Visiting Professor from 09/2009 to 12/2009, and had finished her post doctor research in Central South University, Hunan, China from 04/2009 to 04/2012. | |
